These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34082851)

  • 21. Managing pregnancy in a spinal muscular atrophy type III patient in Indonesia: a case report.
    Setyaningrum CTS; Harahap ISK; Nurputra DK; Rachman IT; Harahap NIF
    J Med Case Rep; 2022 Jan; 16(1):14. PubMed ID: 35033190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spinal muscular atrophies.
    Lancet; 1990 Aug; 336(8710):280-1. PubMed ID: 1973974
    [No Abstract]   [Full Text] [Related]  

  • 23. Yeo and Darras: Extraneuronal Phenotypes of Spinal Muscular Atrophy.
    Yeo CJJ; Darras BT
    Ann Neurol; 2021 Jan; 89(1):24-26. PubMed ID: 33051879
    [No Abstract]   [Full Text] [Related]  

  • 24. A breakthrough effect of gene replacement therapy on respiratory outcomes in children with spinal muscular atrophy.
    AlNaimi A; Hamad SG; Mohamed RBA; Ben-Omran T; Ibrahim K; Osman MFE; Abu-Hasan M
    Pediatr Pulmonol; 2023 Apr; 58(4):1004-1011. PubMed ID: 36533697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [SMA: from gene discovery to gene therapy].
    Barkats M
    Med Sci (Paris); 2020 Feb; 36(2):137-140. PubMed ID: 32129749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic homogeneity between childhood-onset and adult-onset autosomal recessive spinal muscular atrophy.
    Brahe C; Servidei S; Zappata S; Ricci E; Tonali P; Neri G
    Lancet; 1995 Sep; 346(8977):741-2. PubMed ID: 7658877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy.
    Kichula EA; Proud CM; Farrar MA; Kwon JM; Saito K; Desguerre I; McMillan HJ
    Muscle Nerve; 2021 Oct; 64(4):413-427. PubMed ID: 34196026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapy and rehabilitation of the floppy infant.
    Eng GD
    R I Med J (1976); 1989 Oct; 72(10):367-70. PubMed ID: 2595191
    [No Abstract]   [Full Text] [Related]  

  • 29. SMN gene deletions in adult-onset spinal muscular atrophy.
    Clermont O; Burlet P; Lefebvre S; Bürglen L; Munnich A; Melki J
    Lancet; 1995 Dec 23-30; 346(8991-8992):1712-3. PubMed ID: 8551862
    [No Abstract]   [Full Text] [Related]  

  • 30. Gene-Targeted Therapies and Palliative Care in Children with Spinal Muscular Atrophy Type I: No Intrinsic Contradiction.
    von der Hagen M; Nolte-Buchholtz S; Janisch M; Pietz J; Blankenburg M; Ziegler A
    J Palliat Med; 2021 Feb; 24(2):162-163. PubMed ID: 33522861
    [No Abstract]   [Full Text] [Related]  

  • 31. Paradigm shift in the era of disease-modifying therapies for Spinal Muscular Atrophy type 1: respiratory challenges and opportunities.
    Xiao L; Chiang J; Amin R
    Sleep Med; 2021 Oct; 86():113-115. PubMed ID: 34253462
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec -A Single Centre Experience.
    Friese J; Geitmann S; Holzwarth D; Müller N; Sassen R; Baur U; Adler K; Kirschner J
    J Neuromuscul Dis; 2021; 8(2):209-216. PubMed ID: 33427694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes.
    Waldrop MA; Karingada C; Storey MA; Powers B; Iammarino MA; Miller NF; Alfano LN; Noritz G; Rossman I; Ginsberg M; Mosher KA; Broomall E; Goldstein J; Bass N; Lowes LP; Tsao CY; Mendell JR; Connolly AM
    Pediatrics; 2020 Sep; 146(3):. PubMed ID: 32843442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spinal Muscular Atrophy Type 1 With Exon 8 Deletion and Bilateral Optic Atrophy.
    Behera B; Kumar A
    Indian Pediatr; 2020 Dec; 57(12):1191. PubMed ID: 33318336
    [No Abstract]   [Full Text] [Related]  

  • 35. Zolgensma - one-time gene therapy for spinal muscular atrophy.
    Med Lett Drugs Ther; 2019 Jul; 61(1577):113-114. PubMed ID: 31381549
    [No Abstract]   [Full Text] [Related]  

  • 36. [Beyond type I spinal atrophy].
    Mastella C
    Assist Inferm Ric; 1999; 18(4):240-6. PubMed ID: 10833298
    [No Abstract]   [Full Text] [Related]  

  • 37. The genetics of the spinal muscular atrophies.
    Baraitser M
    Prog Clin Biol Res; 1989; 306():75-84. PubMed ID: 2662214
    [No Abstract]   [Full Text] [Related]  

  • 38. Response to letter: A decision for life - Treatment decisions in newly diagnosed families with spinal muscular atrophy.
    Kirschner J; Butoianu N; Goemans N; Haberlova J; Kostera-Pruszczyk A; Mercuri E; van der Pol WL; Quijano-Roy S; Sejersen T; Tizzano EF; Ziegler A; Servais L; Muntoni F
    Eur J Paediatr Neurol; 2021 Jan; 30():103-104. PubMed ID: 33640649
    [No Abstract]   [Full Text] [Related]  

  • 39. Coexistence of Spinal Muscular Atrophy Type 1 and Factor X1 Deficiency.
    Kaya G; Bahadir A; Acar Arslan E
    J Pediatr Hematol Oncol; 2022 Apr; 44(3):115-116. PubMed ID: 33560085
    [No Abstract]   [Full Text] [Related]  

  • 40. Genetic linkage analysis of Canadian spinal muscular atrophy kindreds using flanking microsatellite 5q13 polymorphisms.
    MacKenzie A; Roy N; Besner A; Mettler G; Jacob P; Korneluk R; Surh L
    Hum Genet; 1993 Jan; 90(5):501-4. PubMed ID: 8094064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.